Senti Biosciences (NASDAQ:SNTI) Issues Earnings Results

Senti Biosciences (NASDAQ:SNTI) posted its earnings results on Thursday. The company reported ($0.67) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($3.13) by $2.46, Zacks reports. The business had revenue of $5.86 million during the quarter, compared to analyst estimates of $2.80 million.

Senti Biosciences Trading Up 4.8 %

NASDAQ:SNTI opened at $3.68 on Friday. Senti Biosciences has a 1 year low of $1.52 and a 1 year high of $16.94. The stock has a market cap of $17.77 million, a price-to-earnings ratio of -0.24 and a beta of 2.52. The stock has a 50-day moving average price of $3.93 and a two-hundred day moving average price of $3.45.

Analyst Upgrades and Downgrades

Separately, Chardan Capital reissued a “buy” rating and issued a $10.00 target price on shares of Senti Biosciences in a research note on Monday, December 2nd.

About Senti Biosciences

Senti Biosciences, Inc operates as a preclinical biotechnology company that develops next-generation cell and gene therapies engineered with its gene circuit platform technologies for various diseases. Its lead product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications.